Molecular Diagnostics and Companion Therapies: Partnerships, Payment and Evidence Development
Co-Sponsored by the National Pharmaceutical Council
The promise of molecular diagnostics centers on its ability to use the genetic markers of individual patients to tailor more effective treatment plans. This form of personalized medicine can focus therapy on those who are most likely to respond, enhancing effectiveness and reducing treatment costs over a population. But the pathway to development of personalized approaches based on molecular diagnostics is dependent on securing credible evidence of clinical utility, as well as managing the interplay between diagnostic information and decisions about follow-on treatment.
This meeting of the Health Industry Forum will review the expanding role of molecular diagnostics in our healthcare system as well as potential barriers to adoption. It will examine the business models for developing personalized treatments including the increasingly common collaborations between the drug and diagnostic industries. It will also discuss the evidence payers and consumes will require for adoption, and the role of independent clinical review authorities in setting standards for clinical utility.
Presentations
Molecular Diagnostics and their Evolving Influence on the Healthcare System
Harry Glorikian, Founder and Managing Partner, Scientia Advisors
Delivering Value Through Personalized Medicine: An Industry Perspective
Josephine A. Sollano, DrPH, Head, Global HEOR and Medical Communications, Pfizer Oncology
Opportunities and Challenges in the Development of Companion Diagnostics
E. Patrick Groody, PhD, Divisional Vice President, Research and Development, Abbott Molecular
Payer Perspectives on Molecular Diagnostics
Robert W. Dubois, MD, PhD, Chief Scientific Officer, National Pharmaceutical Council
Molecular Diagnostic Testing Challenges
Elaine Jeter, MD, Medical Director, Palmetto GBA
Personalized Medicine: Perspectives on the New Science of Genetic Testing and Molecular Diagnostics
Lewis G. Sandy, MD, Senior Vice President, Clinical Advancement, UnitedHealth Group
Collaborative Development of Evidentiary Standards for Clinical Utility of MDx
Sean Tunis, MD, MSc, Director, Center for Medical Technology Policy
Biomarkers
Joan McClure, MS, Senior Vice President, Clinical Information and Publications, National Comprehensive Cancer Network